Clinical trial
Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles
NCT07916636 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 21, 2027
- Completion date
- December 1, 2029
- Enrollment
- 100 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cancer, circulating tumor dna detection
Arms
As registered; 2 arms.
-
Cancer patients
Patients with BRCA1-related tumors (e.g., breast, ovarian, or prostate cancer) enrolled at participating hospitals. Approximately 3 mL of EDTA-anticoagulated peripheral blood is collected from each participant. Each sample is tested by both the investigational CRISPR/Cas12a-gold nanoparticle ctDNA detection method and next-generation sequencing (NGS, the gold standard reference), and the results of the two methods are compared to evaluate diagnostic accuracy and sensitivity.
-
Healthy Volunteers
Healthy adults without a history of cancer, enrolled as the control group for specificity assessment. Approximately 3 mL of EDTA-anticoagulated peripheral blood is collected from each participant and tested by the CRISPR/Cas12a-gold nanoparticle method to determine the false positive rate.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Diagnostic accuracy of the CRISPR/Cas12a-gold nanoparticle ctDNA test compared with NGS
The agreement between the CRISPR/Cas12a-gold nanoparticle ctDNA detection method and next-generation sequencing (NGS, the gold standard reference) will be evaluated in tumor patient samples. Diagnostic accuracy is measured by the Kappa coefficient of concordance between the two methods, with Kappa ≥0.85 considered excellent agreement. Sensitivity (detection positive rate of 1 pM, 0.5 pM, and 0.1 pM target ctDNA samples; ≥95% considered qualified) and specificity (false positive rate in 50 healthy volunteer samples; ≤5% considered qualified) will also be assessed.
Lead sponsor's other trials
The First Affiliated Hospital of Zhengzhou University, most recent start first.
+121 more trials
Similar trials
Same condition (Neoplasms) and phase, most recent start first.
+2,727 more trials See the condition page